Sirolimus is under clinical development by OrphAI Therapeutics and currently in Phase II for Bronchiolitis Obliterans.
Medi-Cal’s fragmented system can make moving a nightmare
When Lloyd Tennison moved from Walnut Creek to Stockton last year, he assumed his coverage under Medi-Cal, California’s safety-net health insurance program, would be transferred